Costs
obesity, weight loss
OBESITY
Costs included in the model reflect intervention costs for both ESG and LM, costs associated with the management of AEs, and costs associated with treatment of obesity-related comorbidities (Table ESG costs were based on the cost of the device and hospital costs associated with delivery of the procedure. Costs for LM were applied to both treatment groups and were based on Tier 3 weight management, including healthcare professional visits, with cost categories (GP consultation, nurse consultation, dietician consultation, specialist consultation, consultation, and blood count) and frequency of visits taken from NICE’s appraisal of liraglutide [As the model does not capture subsequent obesity treatment costs (e.g., bariatric procedures for eligible patients in whom treatment does not result in adequate or durable weight loss), LM costs were assumed to be incurred in both treatment groups for the duration of the model horizon. Although it is expected that a proportion of patients will not be compliant with LM medical advice about lifestyle and dietary changes over the duration of the intervention, a 100% compliance rate was assumed in the absence of robust data.Costs for the management of obesity-related comorbidities were based on annual costs identified through a pragmatic literature search [